{"entity": "researcher", "timestamp": "2026-08-22T07:48:32.521Z", "family": "Hovd", "given": "Markus", "initials": "M", "orcid": "0000-0002-6077-0934", "affiliations": ["Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, PO 1068, 0316, Oslo, Norway. m.h.hovd@farmasi.uio.no."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03"}}, "publications": [{"entity": "publication", "iuid": "631b388e809144529cabd94871030e83", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/631b388e809144529cabd94871030e83.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/631b388e809144529cabd94871030e83"}}, "title": "Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance.", "authors": [{"family": "Hovd", "given": "Markus", "initials": "M", "orcid": "0000-0002-6077-0934", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03.json"}}, {"family": "Robertsen", "given": "Ida", "initials": "I"}, {"family": "Johnson", "given": "Line Kristin", "initials": "LK"}, {"family": "Krogstad", "given": "Veronica", "initials": "V"}, {"family": "Wegler", "given": "Christine", "initials": "C"}, {"family": "Kvitne", "given": "Kine Eide", "initials": "KE"}, {"family": "Kringen", "given": "Marianne Kristiansen", "initials": "MK"}, {"family": "Skovlund", "given": "Eva", "initials": "E"}, {"family": "Karlsson", "given": "Cecilia", "initials": "C"}, {"family": "Andersson", "given": "Shalini", "initials": "S"}, {"family": "Artursson", "given": "Per", "initials": "P"}, {"family": "Sandbu", "given": "Rune", "initials": "R"}, {"family": "Hjelmes\u00e6th", "given": "J\u00f8ran", "initials": "J"}, {"family": "\u00c5sberg", "given": "Anders", "initials": "A"}, {"family": "Jansson-L\u00f6fmark", "given": "Rasmus", "initials": "R"}, {"family": "Christensen", "given": "Hege", "initials": "H"}], "type": "journal article", "published": "2023-05-00", "journal": {"title": "Clin Pharmacokinet", "issn": "1179-1926", "volume": "62", "issue": "5", "pages": "725-735", "issn-l": null}, "abstract": "Rosuvastatin pharmacokinetics is mainly dependent on the activity of hepatic uptake transporter OATP1B1. In this study, we aimed to investigate and disentangle the effect of Roux-en-Y gastric bypass (RYGB) and weight loss on oral clearance (CL/F) of rosuvastatin as a measure of OATP1B1-activity.\n\nPatients with severe obesity preparing for RYGB (n = 40) or diet-induced weight loss (n = 40) were included and followed for 2 years, with four 24-hour pharmacokinetic investigations. Both groups underwent a 3-week low-energy diet (LED; < 1200 kcal/day), followed by RYGB or a 6-week very-low-energy diet (VLED; < 800 kcal/day).\n\nA total of 80 patients were included in the RYGB group (40 patients) and diet-group (40 patients). The weight loss was similar between the groups following LED and RYGB. The LED induced a similar (mean [95% CI]) decrease in CL/F in both intervention groups (RYGB: 16% [0, 31], diet: 23% [8, 38]), but neither induced VLED resulted in any further changes in CL/F. At Year 2, CL/F had increased by 21% from baseline in the RYGB group, while it was unaltered in the diet group. Patients expressing the reduced function SLCO1B1 variants (c.521TC/CC) showed similar changes in CL/F over time compared with patients expressing the wild-type variant.\n\nNeither body weight, weight loss nor RYGB per se seem to affect OATP1B1 activity to a clinically relevant degree. Overall, the observed changes in rosuvastatin pharmacokinetics were minor, and unlikely to be of clinical relevance.", "doi": "10.1007/s40262-023-01235-5", "pmid": "36988826", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC10181972"}, {"db": "pii", "key": "10.1007/s40262-023-01235-5"}], "notes": [], "created": "2026-08-21T11:09:34.290Z", "modified": "2026-08-21T11:09:34.373Z"}, {"entity": "publication", "iuid": "efabd2364eb647cebc5a8550720e040b", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/efabd2364eb647cebc5a8550720e040b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/efabd2364eb647cebc5a8550720e040b"}}, "title": "Short- and long-term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity.", "authors": [{"family": "Kvitne", "given": "Kine Eide", "initials": "KE", "orcid": "0000-0001-8118-7660", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2cc96a6df2d34cf7a41eb1fd7ba2887e.json"}}, {"family": "Krogstad", "given": "Veronica", "initials": "V"}, {"family": "Wegler", "given": "Christine", "initials": "C", "orcid": "0000-0002-2810-7518", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fcb45d19c52847f19bd5c0aa296afe10.json"}}, {"family": "Johnson", "given": "Line Kristin", "initials": "LK"}, {"family": "Kringen", "given": "Marianne K", "initials": "MK"}, {"family": "Hovd", "given": "Markus Herberg", "initials": "MH", "orcid": "0000-0002-6077-0934", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/40bec1eda0684e43a25fb3a9552d9f03.json"}}, {"family": "Hertel", "given": "Jens K", "initials": "JK"}, {"family": "Heijer", "given": "Maria", "initials": "M"}, {"family": "Sandbu", "given": "Rune", "initials": "R"}, {"family": "Skovlund", "given": "Eva", "initials": "E"}, {"family": "Artursson", "given": "Per", "initials": "P"}, {"family": "Karlsson", "given": "Cecilia", "initials": "C"}, {"family": "Andersson", "given": "Shalini", "initials": "S"}, {"family": "Andersson", "given": "Tommy B", "initials": "TB"}, {"family": "Hjelmesaeth", "given": "J\u00f8ran", "initials": "J"}, {"family": "\u00c5sberg", "given": "Anders", "initials": "A", "orcid": "0000-0002-0628-1769", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/153c90f914b4461b8fa381a2e24a7954.json"}}, {"family": "Jansson-L\u00f6fmark", "given": "Rasmus", "initials": "R"}, {"family": "Christensen", "given": "Hege", "initials": "H"}, {"family": "Robertsen", "given": "Ida", "initials": "I", "orcid": "0000-0001-9401-7716", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fbbacb93696b4b42b4796fc8a3dab7b2.json"}}], "type": "clinical trial", "published": "2022-09-00", "journal": {"title": "Br J Clin Pharmacol", "issn": "1365-2125", "volume": "88", "issue": "9", "pages": "4121-4133", "issn-l": null}, "abstract": "Roux-en-Y gastric bypass (RYGB) may influence drug disposition due to surgery-induced gastrointestinal alterations and/or subsequent weight loss. The objective was to compare short- and long-term effects of RYGB and diet on the metabolic ratios of paraxanthine/caffeine (cytochrome P450 [CYP] 1A2 activity), 5-hydroxyomeprazole/omeprazole (CYP2C19 activity) and losartan/losartan carboxylic acid (CYP2C9 activity), and cross-sectionally compare these CYP-activities with normal-to-overweight controls.\n\nThis trial included patients with severe obesity preparing for RYGB (n = 40) or diet-induced (n = 41) weight loss, and controls (n = 18). Both weight loss groups underwent a 3-week low-energy diet (<1200 kcal/day, weeks 0-3) followed by a 6-week very-low-energy diet or RYGB (both <800 kcal/day, weeks 3-9). Follow-up time was 2 years, with four pharmacokinetic investigations.\n\nMean \u00b1 SD weight loss from baseline was similar in the RYGB-group (13 \u00b1 2.4%) and the diet group (10.5 \u00b1 3.9%) at week 9, but differed at year 2 (RYGB -30 \u00b1 6.9%, diet -3.1 \u00b1 6.3%). From weeks 0 to 3, mean (95% confidence interval [CI]) CYP2C19 activity similarly increased in both groups (RYGB 43% [16, 55], diet 48% [22, 60]). Mean CYP2C19 activity increased by 30% (2.6, 43) after RYGB (weeks 3-9), but not in the diet-group (between-group difference -0.30 [-0.63, 0.03]). CYP2C19 activity remained elevated in the RYGB group at year 2. Baseline CYP2C19 activity was 2.7-fold higher in controls compared with patients with obesity, whereas no difference was observed in CYP1A2 and CYP2C9 activities.\n\nOur findings suggest that CYP2C19 activity is lower in patients with obesity and increases following weight loss. This may be clinically relevant for drug dosing. No clinically significant effect on CYP1A2 and CYP2C9 activities was observed.", "doi": "10.1111/bcp.15349", "pmid": "35404513", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC9541356"}], "notes": [], "created": "2026-08-21T12:17:28.245Z", "modified": "2026-08-21T12:17:28.434Z"}]}